Armata Pharmaceuticals gets FDA Breakthrough for AP-SA02
U.S. FDA granted Breakthrough Therapy Designation for AP-SA02 in patients with complicated Staphylococcus aureus bacteremia, citing Phase 2 clinical data.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.